Item 8.01 Other Events.

On October 24, 2012, the Akorn, Inc. (the "Company") issued a press release announcing that its development and manufacturing partner, Sofgen Pharmaceuticals, LLC, ("Sofgen") received approval from the U.S. Food and Drug Administration ("FDA") for its abbreviated new drug application for Progesterone capsules, 100mg and 200mg, and that the Company, which has exclusive marketing rights in the U.S., has begun distribution of the product. Progesterone capsules are the generic of Abbott Laboratories' Prometrium® capsules, which are indicated for the treatment of endometrial hyperplasia and secondary amenorrhea.